Skip to main content
SpringerLink
Log in

Hormonrezeptor-positive prämenopausale Patientinnen mit metastasiertem Mammakarzinom

Länger progressionsfrei unter Ribociclib in Kombination mit endokriner Therapie

  • journal club
  • Published:
InFo Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Tripathy D et al. SABCS. 2017;Abstr GS2-05.

  2. Kwapisz D et al. Breast Cancer Res Treat. 2017;166(1):41–54.

    Article  CAS  Google Scholar 

  3. Hortobagyi GN et al. N Engl J Med. 2016;375(18):1738–48.

    Article  CAS  Google Scholar 

  4. DeSantis CE et al. CA Cancer J Clin. 2017;67(6):439–48.

    Article  Google Scholar 

  5. Anders CK et al. J Clin Oncol. 2008;26(20):3324–30.

    Article  Google Scholar 

  6. Schrijver WAME et al. J Natl Cancer Inst. 2018;https://doi.org/cnfv.

  7. Etchegoyen CV et al. Curr Clin Pharmacol. 2018;http://doi.org/cnfw.

  8. Tripathy D et al. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. SABCS. 2017;Abstr GS2-05.

Download references

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik Tübingen, Tübingen, Deutschland

    Christina Barbara Walter

Authors
  1. Christina Barbara Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Barbara Walter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walter, C.B. Länger progressionsfrei unter Ribociclib in Kombination mit endokriner Therapie. Info Onkol. 21, 15–16 (2018). https://doi.org/10.1007/s15004-018-6088-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-018-6088-2

Search

Navigation